노인의 임상시험 참여에 대한 현황과 향후 발전 방향 : 임상시험 전문가를 대상으로 한 설문조사 분석 = Current State and Future Improvement of the Elderly Participation in Clinical Trials

다국어 초록 (Multilingual Abstract)

Background: Clinical trials are widely used to approve the efficacy and discover adverse reactions of new drugs. However, there has been much concern about the unjustified exclusion of the older adults in clinical trials. The purpose of this study was to assess ageism in clinical trials and to find solution to any discovered discrimination.
Methods: An online questionnaire was completed by 1,650 experts including doctors, pharmaceutical staff, and contract research organization members. An offline inquiry was conducted by 250 experienced professors from a single tertiary hospital and other allied professions. The questions covered the current state of elderly participation, possible reasons for under-representation, and plans for its solution.
Results: Among 1,900 subjects, 246 (12.9%) individuals completed the survey. We excluded the six subjects who did not answer more than 10 questions, and analyzed the remaining 240 respondents. They agreed that there are tendencies to exclude the aged from clinical trials (69.2%), and that under-representation would cause difficulties for doctors and geriatric patients. Most people (84.6%) thought that treating older adults with the results from trials which exclude aged participants is inappropriate. Because respondents had difficulties explaining the trial process and obtaining informed consent, they thought establishing a geriatric clinical trial team would be highly effective. Experts also believed that financial inducements and legal regulations are required to increase elderly enrollment.
Conclusion: Because the elderly have a unique physiology, the participation of older adults in clinical research is indispensable for verifying efficacy and determining potential adverse reactions. Consequently, clinical research professionals should be concerned about the participation of older subjects, and the authorities must begin to care about age discrimination in research fields.

참고문헌 (Reference)

1 Guyatt GH., "Users’ guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? Evidence-Based Medicine Working Group" 270 : 2598-2601, 1993

2 Guyatt GH., "Users’ Guides to the Medical Literature : XXV. Evidence-based medicine : principles for applying the Users’ Guides to patient care. Evidence-Based Medicine Working Group" 284 : 1290-1296, 2000

3 Cruz-Jentoft AJ., "Upper age limits in studies submitted to a research ethics committee" 22 : 175-178, 2010

4 Bayer A., "Unjustified exclusion of elderly people from studies submitted to research ethics committee for approval : descriptive study" 321 : 992-993, 2000

5 McMurray JJ., "Treatment of heart failure with spironolactone : trial and tribulations" 351 : 526-528, 2004

6 Britton A., "Threats to applicability of randomised trials : exclusions and selective participation" 4 : 112-121, 1999

7 Cherubini A., "The persistent exclusion of older patients from ongoing clinical trials regarding heart failure" 171 : 550-556, 2011

8 Gurwitz JH., "The exclusion of the elderly and women from clinical trials in acute myocardial infarction" 268 : 1417-1422, 1992

9 Pitt B., "The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators" 341 : 709-717, 1999

10 Temple R., "The Oxford textbook of clinical research ethics" Oxford University Press 577-588, 2011

11 Townsley CA., "Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials" 23 : 3112-3124, 2005

12 Health Insurance Review & Assessment Service., "Statistics of total medical expenses: 2008-2012" Health Insurance Review & Assessment Service 2012

13 Juurlink DN., "Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study" 351 : 543-551, 2004

14 Statistics Korea., "Population projections for Korea: 2010-2060" Statistics Korea 2011

15 Son Y., "Points to consider in the evaluation of biopharmaceuticals : review of quality control" 1 : 15-23, 2006

16 Fudge N., "Involving older people in health research" 36 : 492-500, 2007

17 Barron JS., "Informed consent for research participation in frail older persons" 16 : 79-85, 2004

18 McMurdo ME., "Including older people in clinical research" 331 : 1036-1037, 2005

19 Food and Drug Administration., "Guideline for the study of drugs likely to be used in the elderly" Food and Drug Administration

20 Working Group on Functional Outcome Measures for Clinical Trials., "Functional outcomes for clinical trials in frail older persons : time to be moving" 63 : 160-164, 2008

21 Cherubini A., "Fighting against age discrimination in clinical trials" 58 : 1791-1796, 2010

22 Bugeja G., "Exclusion of elderly people from clinical research : a descriptive study of published reports" 315 : 1059-, 1997

23 Van Spall HG., "Eligibility criteria of randomized controlled trials published in high-impact general medical journals : a systematic sampling review" 297 : 1233-1240, 2007

24 Mo SH., "Decision-making power of the elderly in the family" 11 : 50-60, 1991

25 Greenlee RT., "Cancer statistics, 2000" 50 : 7-33, 2000

26 Johnson CL., "A longitudinal study of family supports to impaired elderly" 23 : 612-618, 1983